AstraZeneca (AZN) Tops Q1 EPS by 110c; reaffirms guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line
April 25, 2024 5:50 AM EDTAstraZeneca (NASDAQ: AZN) shares rose 5.1% in London trading Thursday after the drugmaker smashed analyst expectations for Q1 earnings and revenue.
The company posted earnings per share (EPS) of $2.06, beating the consensus estimates of $1.10. Revenue stood at $12.68 billion, also above the estimated $11.79... More
